Clinical TrialsAzenosertib's combination therapy showed promising safety and early proof-of-concept for synergy with other agents, suggesting potential future benefits.
Financial PositionZNTL reported cash and cash equivalents of $333mn, which they expect to provide runway into late 2027.
Regulatory PathwayGiven its fast track designation, if results are positive, accelerated approval may be on the table.